Last reviewed · How we verify

NCT04609618

Evaluatation of Appscent Device Safety and Effectiveness for Relief of Obstructive Sleep Apnea (OSA) Syndrome in Adults.

Completed EARLY_PHASE1 Last updated 4 January 2023
What this trial tests

EARLY_PHASE1 trial testing Appscent Device in Obstructive Sleep Apnea in 23 participants. Completed in 26 August 2021.

Timeline
15 October 2020
Primary endpoint
26 August 2021
26 August 2021

Quick facts

Lead sponsorY.A. Appscent Ltd.
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment23
Start date15 October 2020
Primary completion26 August 2021
Estimated completion26 August 2021
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Y.A. Appscent Ltd.

Who can join

Adults 40 to 70, any sex, with Obstructive Sleep Apnea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Obstructive Sleep Apnea (OSA) syndrome is a disorder characterized by repetitive episodes of upper airway obstruction that occur during sleep. The standard treatment for apnea remains a device consisting of a pump and nasal mask that provide continuous positive airway pressure (CPAP). The major disadvantage of CPAP is the relatively low compliance. Appscent developed a non-contact effortless bedside solution based on the following: odors modify respiratory patterns during wake . Mildly trigeminal and pure olfactory odorants do not arouse or wake.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Respiration-triggered olfactory stimulation reduces obstructive sleep apnea severity: A prospective pilot study.
    Perl O, Kemer L, Green A, Arish N, et al · · 2024 · cited 2× · PMID 38740050 · DOI 10.1111/jsr.14236

Verify or expand the search:

Other recruiting trials for Obstructive Sleep Apnea

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04609618.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing